TABLE I.
Agent | Target |
---|---|
Ipilimumab | CTLA-4 |
Nivolumab | PD-1 |
Pembrolizumab | PD-1 |
Atezolizumab | PD-L1 |
Durvalumab | PD-L1 |
Avelumab | PD-L1 |
CTLA-4 = cytotoxic T lymphocyte–associated protein 4; PD-1 = programmed cell death 1; PD-L1 = programmed cell death ligand 1.